山东未名生物医药股份有限公司 监事会关于公司 2023 年股票期权激励计划第二个行权期行 权条件未成就及注销部分股票期权的核查意见 山东未名生物医药股份有限公司（以下简称"公司"）监事会根据《中华人 民共和国公司法》《中华人民共和国证券法》《上市公司股权激励管理办法》《深 圳证券交易所上市公司自律监管指南第 1 号——业务办理》等有关法律、法规和 规范性文件以及《山东未名生物医药股份有限公司 2023 年股票期权激励计划（草 案）》《公司章程》的规定，对公司 2023 年股票期权激励计划第二个行权期行 权条件未成就及注销部分股票期权事项进行审核，发表核查意见如下： 综上，监事会同意公司 2023 年股票期权激励计划第二个行权期行权条件未 成就及注销部分股票期权事项。 山东未名生物医药股份有限公司 监 事 会 2025 年 4 月 28 日 本次注销 2023 年股票期权激励计划授予的股票期权第二个行权期行权条件 未成就以及部分激励对象因个人原因离职不再具备激励资格的股票期权事宜，符 合《上市公司股权激励管理办法》等法律法规、规范性文件及公司《2023 年激 励计划》的规定，决策审批程序合法、合规，不存在损害公 ...

| 名称 | 持有数量(万股) | 占总股本比例(%) | 增减情况(万股) | | --- | --- | --- | --- | | 高宝林 | 7382.28 | 18.42 | 不变 | | 石庭波 | 883.13 | 2.20 | 不变 | | 陈寿丰 | 706.00 | 1.76 | 不变 | | 申万宏源证券（000562）有限公司 | 579.30 | 1.45 | -2.15 | | 朱燕珍 | 317.91 | 0.79 | -101.59 | | 蔡文彬 | 291.31 | 0.73 | 27.46 | | 中信建投（601066）证券股份有限公司 | 263.68 | 0.66 | -10.03 | | 南方中证1000ETF | 247.17 | 0.62 | -26.87 | | 陈豪 | 241.17 | 0.60 | 新进 | | 香港中央结算有限公司 | 237.85 | 0.59 | -176.06 | | 较上个报告期退出前十大股东有 | | | | | 杨晓东 | 447.00 | 1.12 | 退出 | 三、分红送配方案情况 本次公司不分配不转赠。 数据四舍五入 ...

浙江天册（深圳）律师事务所 关于 山东未名生物医药股份有限公司 2023 年股票期权激励计划 注销部分股票期权事项的 法律意见书 中国广东省深圳市南山区科发路 222 号康泰创新广场 34 楼 518057 电话：0755-83739000 传真：0755-26906383 致：山东未名生物医药股份有限公司 浙江天册（深圳）律师事务所（以下简称本所）受山东未名生物医药股份有 限公司（以下简称未名医药或公司）委托，担任公司实施 2023 年股票期权激励 计划（以下简称本次激励计划）的专项法律顾问。本所根据《中华人民共和国公 司法》（以下简称《公司法》）、《中华人民共和国证券法》（以下简称《证券 法》）、《上市公司股权激励管理办法》（以下简称《管理办法》）等法律、行 政法规、部门规章及其他规范性文件（以下合称法律法规）及《山东未名生物医 药股份有限公司章程》（以下简称《公司章程》）、《山东未名生物医药股份有 限公司 2023 年股票期权激励计划（草案）》（以下简称《激励计划（草案）》） 的有关规定，就未名医药本次激励计划注销部分股票期权（以下简称本次注销） 相关事项出具本法律意见书。 为出具本法律意见书，本所律师 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥35,329,856.70, a decrease of 57.84% compared to ¥83,804,783.29 in the same period last year[5] - The net loss attributable to shareholders was ¥36,850,397.17, representing a 33.01% increase from a loss of ¥27,704,081.15 in the previous year[5] - The net cash flow from operating activities was -¥58,614,130.67, a significant decline of 285.59% compared to -¥15,200,975.67 in the same period last year[5] - The basic and diluted earnings per share were both -¥0.0559, a decrease of 33.10% from -¥0.0420 in the previous year[5] - The company reported a 57.84% decrease in operating income primarily due to product recalls[13] - Total operating revenue for the current period is CNY 35,329,856.70, a decrease of 57.8% compared to CNY 83,804,783.29 in the previous period[28] - Net profit for the current period is a loss of CNY 49,818,616.89, compared to a loss of CNY 27,055,340.81 in the previous period, indicating a worsening financial performance[29] - The net profit attributable to the parent company was -36,850,397.17 yuan, compared to -27,704,081.15 yuan in the previous period, indicating a decline[30] - The total comprehensive income amounted to -49,818,616.89 yuan, compared to -27,055,340.81 yuan in the previous period[30] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,167,843,796.67, down 1.28% from ¥2,195,918,588.20 at the end of the previous year[5] - The balance of other receivables increased by 97.55% compared to the beginning of the year, mainly due to prepayments made for the industrial park[8] - The balance of contract liabilities increased by 160.57% compared to the beginning of the year, attributed to pre-received contract payments[10] - Total current assets decreased to CNY 729,876,009.75 from CNY 747,007,338.19, a decline of 2.3%[26] - Total liabilities increased to CNY 190,692,131.12 from CNY 173,612,003.09, an increase of 9.9%[27] - Long-term equity investments slightly decreased to CNY 1,048,822,473.33 from CNY 1,055,730,183.04, a decrease of 0.7%[26] Cash Flow - The company reported a decrease in cash and cash equivalents from RMB 506,403,730.00 at the beginning of the period to RMB 445,010,515.55 at the end of the period[25] - The company’s cash flow management remains a focus, with a significant reduction in cash reserves noted[25] - Cash inflows from operating activities totaled 67,021,948.27 yuan, down from 103,266,237.28 yuan in the previous period[32] - The net cash flow from operating activities was -58,614,130.67 yuan, compared to -15,200,975.67 yuan in the previous period[32] - The cash and cash equivalents at the end of the period were 442,764,542.95 yuan, down from 504,337,388.39 yuan at the beginning of the period[33] - The net cash increase in cash and cash equivalents was -61,572,845.44 yuan, compared to an increase of 63,453,004.06 yuan in the previous period[32] Expenses and Costs - Total operating costs for the current period amount to CNY 79,830,761.69, down 25.0% from CNY 106,361,412.35 in the previous period[29] - Research and development expenses for the current period were CNY 4,880,913.96, down 21.4% from CNY 6,208,293.77 in the previous period[29] - The company reported a financial cost of CNY -803,773.97, indicating a reduction in financial expenses compared to CNY -277,387.95 in the previous period[29] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 38,037[18] - The company’s top 10 unrestricted shareholders include Shenzhen Yilian Technology Co., Ltd. with 25,204,000 shares, accounting for 3.82%[19] - The company has not disclosed any changes in the participation of major shareholders in margin trading and securities lending activities[19] - The company has not identified any related party relationships or concerted actions among the top 10 shareholders[19] Corporate Actions and Agreements - The company approved a capital increase of RMB 290 million for its wholly-owned subsidiary, Shandong Yandu Biotechnology Co., Ltd., raising its registered capital to RMB 300 million[22] - The company signed a clinical trial technical service agreement for the Phase III clinical trial of recombinant human nerve growth factor eye drops with Tianjin Happy Life Technology Co., Ltd.[21] - The company plans to sign a general contracting agreement for the cleanroom and electromechanical project of the Shandong Weiming Biomedical Industrial Park with Shandong Zhongda Engineering Technology Co., Ltd.[23] - The company’s wholly-owned subsidiary will procure necessary systems and materials for the production workshop of recombinant human nerve growth factor eye drops from Jiangsu Suhao Innovation Technology Group Co., Ltd.[24] Compliance and Reporting - The company did not undergo an audit for the first quarter report[34] - The report was issued by the Board of Directors on April 28, 2025[35]

Core Viewpoint - Unimed Pharmaceutical's subsidiary, Tianjin Unimed, has been suspended from production and sales due to regulatory measures, significantly impacting the company's operations and revenue potential [2][3]. Group 1: Company Operations - Tianjin Unimed, primarily engaged in the production and sales of interferon drugs, generated revenue of 217 million yuan in 2024, accounting for 60.09% of Unimed Pharmaceutical's total revenue [2]. - The company's interferon business achieved revenue of 303 million yuan in 2023, representing 70.47% of total revenue, an increase from approximately 229 million yuan in 2022, which was 64.27% of total revenue [3]. - The main products contributing to Unimed's revenue are nerve growth factor and interferon products, which together account for over 90% of total revenue, with both categories having a gross margin close to 80% [2]. Group 2: Regulatory Issues - The suspension of Tianjin Unimed's production and sales is due to the interferon α2b spray being found non-compliant with biological activity standards, leading to procurement suspensions in multiple regions [2]. - The company must complete rectification and inspection to resume production, and products must meet national standards before being sold again [3]. - If the suspension lasts longer than three months, it may trigger additional risk warnings for the company [2].

每经记者 彭斐 每经编辑 马子卿 刚发布亏损业绩的未名医药（SZ002581，股价7.42元，市值48.95亿元），其贡献六成营收的控股子公 司停产，再给上市公司一记"重锤"。 未名医药4月25日公告显示，公司控股子公司天津未名生物医药有限公司（以下简称"天津未名"）于4月 22日被天津市药品监督管理局采取暂停生产、销售风险控制措施。 受天津未名事件影响，4月25日开盘，未名医药股价跌停。截至当日收盘，未名医药报7.42元/股，下跌 9.95%，当前市值为48.95亿元。 值得注意的是，天津未名需完成整改验收工作，方能恢复生产，暂停销售的产品需要按国家药监局标准 检验合格后方能重新销售使用。在此期间，天津未名的销售及回款将受到不利影响。 核心产品被多地暂停采购 未名医药提到，天津未名需完成整改验收工作，方能恢复生产，暂停销售的产品需要按国家药监局标准 检验合格后方能重新销售使用。在此期间，天津未名的销售及回款将受到不利影响。 《每日经济新闻》记者注意到，天津未名近期麻烦缠身。4月21日，上海市医药集中招标采购事务管理 所发布通知，暂停天津未名生产的人干扰素α2b喷雾剂采购资格。此外，浙江、内蒙古、西藏相关部门 ...

未名医药（002581.SZ）正经历成立以来最严峻的生存考验。 4月24日晚间，未名医药连发公告披露，天津市药监局在药品GMP符合性检查中发现天津未名（下称"天津未名"）存在严重生产管理缺陷，决定对其采取暂 停生产、销售的风险控制措施。 这家曾凭借干扰素产品风光无限的生物医药企业，因核心子公司天津未名生产质量管理体系全面失控，触发监管部门重拳整治。 财务数据显示，天津未名2024年实现营收2.17亿元，占上市公司总营收的60.09%。其中干扰素产品近三年贡献率持续超过70%，2024年毛利率更达 79.92%。 该子公司主营的人干扰素α2b系列产品，正是支撑未名医药六成营收的"生命线"。 消息影响下，未名医药今日开盘便大幅跳水低开后火速跌停，截至收盘，报7.42元/股，跌停板最高封单额超4392万元，总市值48.95亿元。 六成营收命悬一线 | | 营业收入 | 营业成本 | 毛利率 | 营业收入比上 年同期增减 | 营业成本比上. 年同期增减 | 毛利率比上年 同期增减 | | --- | --- | --- | --- | --- | --- | --- | | 分行业 | | | | | | | | 生 ...

Core Viewpoint - Unimed Pharmaceutical faces significant operational challenges due to regulatory issues with its subsidiary Tianjin Weiming Biopharmaceutical Co., which has been ordered to suspend production and sales due to non-compliance with drug production quality management standards [1][2]. Group 1: Regulatory Issues - Tianjin Weiming was found to have production practices that do not meet the 2010 revised Drug Production Quality Management Standards, leading to a suspension of production and sales [1]. - The company must complete rectification and inspection before resuming production, which could take up to three months [1]. - If production is not restored within three months, Unimed may face additional risk warnings and could be subject to special treatment (ST) [1]. Group 2: Financial Impact - Following the announcement, Unimed's stock price dropped by 9.95%, closing at 7.42 yuan per share, with a market capitalization of 4.895 billion yuan [1]. - In 2024, Tianjin Weiming generated revenue of 217 million yuan, accounting for 60.09% of Unimed's total revenue, but reported a net loss of 14.0037 million yuan [1][2]. - The recall of a specific batch of interferon α2b spray due to non-compliance resulted in a revenue reduction of 23.1672 million yuan for Unimed [2]. Group 3: Historical Performance - Unimed has experienced fluctuating performance, with five out of the last seven years resulting in losses, particularly since 2018 [3]. - The company has faced multiple operational setbacks, including the suspension of its subsidiary Weiming Tianyuan due to environmental regulations and significant revenue declines in its core products [3][4]. - The ongoing control disputes over Beijing Kexing have further complicated Unimed's operational stability and financial performance [4]. Group 4: Current Business Structure - Unimed's operations are heavily reliant on three key subsidiaries: Tianjin Weiming, Xiamen Weiming, and Beijing Kexing [5]. - The revenue from the previously significant product, nerve growth factor, has decreased to 139 million yuan, representing only 38.59% of total revenue in 2024 [5]. - With Tianjin Weiming's current regulatory issues, Unimed faces potential operational crises as it relies on this subsidiary for a substantial portion of its income [5].

药品生产质量管理规范是不可触碰的红线，任何违规行为都将受到严厉处罚。笔者认为，未名医药公司 需要加强内部管理，完善质量控制体系，应始终将药品质量和患者安全放在首位，确保未来不再出现类 似问题，重新赢得市场的信任。 天津未名是未名医药的重要子公司。天津未名被暂停生产的原因是其相关药品生产行为不符合《药品生 产质量管理规范》(2010年修订)要求。这一问题的暴露，反映出公司在质量管理方面存在严重漏洞，也 凸显了其在内部控制和合规管理上的不足。药品生产质量管理规范是保障药品质量和安全的基本要求， 任何不符合规范的行为都可能对患者的生命健康造成威胁。这一事件不仅引发了市场的广泛关注，也为 整个行业敲响了警钟。 对于未名医药而言，子公司被暂停生产不仅影响了公司的短期经营业绩，还可能对公司的长期发展带来 深远影响。2024年，未名医药实现营业收入3.60亿元，同比减少16.14%；归母净利润-1.37亿元，亏损同 比扩大58.70%。此次子公司停产，或将进一步加剧公司的经营困境，影响投资者的信心和公司的市场 形象。4月25日，未名医药股价盘中跌停。 未名医药虽表示已成立专项整改小组，全面排查问题根源，制定整改方案，争取尽 ...